Voraxaze® (glucarpidase) reduced plasma MTX concentrations by ≥97% within 15 minutes in all 22 treatment-evaluable patients
Patients can achieve clinically important reductions in plasma MTX concentrations within 15 min vs 5 to 11 days
Patients who received treatment with Voraxaze® (glucarpidase) ≤4 days experienced significantly lower rates of Grade 4 toxicity and mortality associated with MTX.3,4
*Excluding hematologic, hepatic, or renal adverse reactions.1
✝This adverse reaction includes the following terms: ushing, feeling hot, burning sensation.1
Watch the mechanism of action video:
Effective nonrenal elimination of MTX with Voraxaze® (glucarpidase)
Select CONTINUE to proceed to the BTG Pharmaceuticals website.